Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15010837 | 0.86 | ALDH1A1 (0.40) | NR4A2ALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL17552284 | 0.85 | ALDH1A1 (0.39) | DYRK1BRIPK2KCNH2NR4A2AXL | |
| SCHEMBL30880575 | 0.85 | RIPK2 (0.50) | DYRK1BRIPK2KCNH2KDRRET | |
| SCHEMBL2595325 | 0.85 | CA9 (0.50) | NR4A2CA9TDP1 | |
| SCHEMBL600488 | 0.85 | RIPK2 (0.50) | DYRK1BRIPK2KCNH2KDRRET | |
| SCHEMBL4005800 | 0.82 | RIPK2 (0.42) | DYRK1BRIPK2KCNH2NR4A2KDR | |
| SCHEMBL2594512 | 0.82 | CYP1A2 (0.40) | DYRK1BRIPK2KCNH2KDRRET | |
| SCHEMBL600081 | 0.81 | RIPK2 (0.58) | DYRK1BRIPK2KCNH2NR4A2KDR | |
| SCHEMBL1775199 | 0.81 | PDE4B (0.45) | DYRK1BKCNH2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL14727530 | 0.81 | VCAM1 (0.50) | RIPK2KCNH2ALDH1A1PIK3CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4622970-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| EP-2566477-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-02 | — | — | EP | disclosed |
| EP-2566477-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | RIPK1, RIPK2, RIPK4 | DYRK1B 1608/4885RIPK2 2/4885KCNH2 3002/4885 |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | DYRK1B 419/4885RIPK2 326/4885KCNH2 1159/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | DYRK1B 865/4885RIPK2 1/4885KCNH2 3932/4885 |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | DYRK1B 419/4885RIPK2 326/4885KCNH2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.